uniQure (NASDAQ:QURE) Price Target Raised to $32.00 at Stifel Nicolaus

uniQure (NASDAQ:QURE) had its price objective lifted by Stifel Nicolaus from $12.00 to $32.00 in a research note issued to investors on Monday,Benzinga reports. They currently have a buy rating on the biotechnology company’s stock.

A number of other analysts also recently weighed in on QURE. StockNews.com upgraded uniQure to a “sell” rating in a research report on Wednesday, December 11th. Royal Bank of Canada boosted their price objective on shares of uniQure from $14.00 to $20.00 and gave the stock an “outperform” rating in a report on Wednesday, December 11th. HC Wainwright reaffirmed a “buy” rating and issued a $25.00 price objective on shares of uniQure in a research note on Tuesday, December 10th. Raymond James upgraded shares of uniQure from an “outperform” rating to a “strong-buy” rating and lifted their target price for the stock from $20.00 to $52.00 in a research report on Tuesday, December 10th. Finally, Cantor Fitzgerald upped their price target on shares of uniQure from $28.00 to $58.00 and gave the company an “overweight” rating in a research report on Tuesday, December 10th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, six have issued a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $32.13.

uniQure Stock Performance

uniQure stock opened at $17.40 on Monday. uniQure has a fifty-two week low of $3.73 and a fifty-two week high of $17.71. The company has a debt-to-equity ratio of 0.92, a quick ratio of 6.51 and a current ratio of 6.51. The stock has a market cap of $848.13 million, a P/E ratio of -3.36 and a beta of 0.89. The firm’s fifty day moving average price is $7.04 and its 200-day moving average price is $6.38.

uniQure (NASDAQ:QURE) last released its earnings results on Tuesday, November 5th. The biotechnology company reported ($0.91) EPS for the quarter, beating analysts’ consensus estimates of ($1.12) by $0.21. uniQure had a negative return on equity of 188.82% and a negative net margin of 837.80%. The business had revenue of $2.29 million for the quarter, compared to analysts’ expectations of $2.73 million. On average, equities research analysts expect that uniQure will post -3.82 earnings per share for the current fiscal year.

Insider Activity

In other news, CEO Matthew C. Kapusta sold 3,418 shares of uniQure stock in a transaction that occurred on Monday, December 9th. The stock was sold at an average price of $7.63, for a total value of $26,079.34. Following the sale, the chief executive officer now directly owns 597,915 shares in the company, valued at approximately $4,562,091.45. This trade represents a 0.57 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 4.74% of the company’s stock.

Institutional Trading of uniQure

A number of institutional investors and hedge funds have recently added to or reduced their stakes in QURE. Vanguard Personalized Indexing Management LLC increased its position in uniQure by 21.0% during the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 13,301 shares of the biotechnology company’s stock valued at $59,000 after purchasing an additional 2,306 shares during the period. China Universal Asset Management Co. Ltd. increased its position in shares of uniQure by 57.0% during the third quarter. China Universal Asset Management Co. Ltd. now owns 10,093 shares of the biotechnology company’s stock valued at $50,000 after buying an additional 3,663 shares during the period. Geode Capital Management LLC increased its position in shares of uniQure by 1.3% during the third quarter. Geode Capital Management LLC now owns 508,602 shares of the biotechnology company’s stock valued at $2,509,000 after buying an additional 6,362 shares during the period. American Century Companies Inc. raised its stake in uniQure by 14.6% in the second quarter. American Century Companies Inc. now owns 67,699 shares of the biotechnology company’s stock worth $303,000 after buying an additional 8,642 shares in the last quarter. Finally, RTW Investments LP purchased a new stake in uniQure in the third quarter worth about $49,000. Hedge funds and other institutional investors own 78.83% of the company’s stock.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.